FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220884345> ?p ?o ?g. }

• W4220884345 endingPage "11" @default.
• W4220884345 startingPage "P5" @default.
• W4220884345 abstract "Abstract Background: Ipat is a potent oral AKT inhibitor that has been studied in multiple clinical trials, primarily in breast and prostate cancers. Combining fulv and AKT inhibition demonstrated efficacy in pts with HR+ aBC regardless of PI3K/AKT pathway alterations [Jones, Lancet Oncol 2020]. IPATunity150 (NCT04060862) was designed as a phase III trial with an open-label phase Ib portion adding ipat to palbo plus fulv in biomarker-unselected HR+ HER2-negative aBC. The biological rationale was to prevent or delay resistance to CDK4/6 inhibition plus endocrine therapy (ET). AKT1 alterations and PTEN loss have been implicated in resistance to CDK4/6 inhibitors [Wander, Cancer Discov 2020; Costa, Cancer Discov 2020]. We report results from the open-label phase Ib portion. Patients and Methods: The primary objective was to assess safety and pharmacokinetics (PK) of ipat in combination with palbo and fulv; several efficacy parameters were also analyzed. Pts with measurable disease who had not previously received a CDK4/6 inhibitor and had experienced relapse during adjuvant ET were treated with ipat at a dose of 300 mg/d, d1-21 q28d, plus standard-of-care doses of palbo (125 mg/d, d1-21 q28d) plus fulv (500 mg q28d with a loading dose in cycle 1). The selected ipat dose was lower than the 400 mg typically used in other studies because of the anticipated drug-drug interaction (DDI) when combining ipat (a sensitive CYP3A4 substrate and mild-to-moderate CYP3A inhibitor) with palbo (a weak time-dependent CYP3A4 inhibitor and CYP3A substrate). Results: Of the 20 pts treated, 20% were Asian, 65% had primary endocrine resistance (relapse ≤2 years after starting adjuvant ET), 80% had received prior (neo)adjuvant chemotherapy, and 60% had liver and/or lung metastases. At the data cutoff (19 Mar 2021; median follow-up 6.1 months), median treatment duration was 5.1, 5.9, and 5.3 months for ipat, palbo, and fulv, respectively. Treatment was ongoing in 13 pts. Grade 3/4 adverse events (AEs) occurred in 80% of pts (no grade 5). The most common AEs were diarrhea (80% any grade, 10% grade 3, no grade 4) and neutropenia (75% any grade, 45% grade 3, 20% grade 4). Other notable grade ≥3 AEs were grade 3 liver function test elevations in 10%. There were no cases of febrile neutropenia and only 1 case of pneumonitis (grade 1). AEs led to at least one dose reduction of ipat in 6 pts (30%; diarrhea n=3 [with vomiting in 1 pt], neutropenia n=3 [with fatigue in 1 pt]) and of palbo in 9 pts (45%; all for neutropenia). One pt (5%) discontinued ipat and palbo permanently due to ongoing neutropenia after protocol-defined dose reductions. As expected, a DDI led to increased ipat exposure (AUC0-24,ss ~60% and Cmax ~40%) when ipat and palbo were combined. Based on population PK analysis, palbo AUC0-24,ss was ~30% higher than reported from the PALOMA 1 and 2 trials, which was expected and consistent with previously reported physiologically based PK modeling of palbo exposure when administered with moderate CYP3A inhibitors [Yu, J Clin Pharmacol 2017]. All 20 pts had at least one post-baseline tumor assessment. Best overall response rate was 45% (95% CI: 23-68%), including confirmed responses in 7 pts (35%; 5% complete response, 30% partial response) at the clinical cutoff date. Median duration of response was 9.6 months (95% CI: 7.1-not estimable). An additional 10 pts (50%) had stable disease. Progression-free survival results were immature (events in 7 pts). There was no obvious association between efficacy and mutations in PIK3CA/AKT1 as tested in ctDNA. Conclusion: The triplet combination of ipat, fulv, and palbo had an acceptable safety profile generally consistent with that of the individual study drugs; ipat exposure was increased through a predicted DDI. Updated results will be presented. Citation Format: Mafalda Oliveira, Aditya Bardia, Sung-Bae Kim, Naoki Niikura, Cristina Hernando, Gustavo Werutsky, Yoland Antill, Pedro Liedke, Catherine Oakman, Eriko Tokunaga, Seth Wander, Vanessa Krause, Toshinari Yamashita, Frauke Schimmoller, Jacob Rotmensch, Heidi Savage, Rucha Sane, Nicholas Turner. Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-16-11." @default.
• W4220884345 created "2022-04-03" @default.
• W4220884345 creator A5003095638 @default.
• W4220884345 creator A5011644667 @default.
• W4220884345 creator A5014596231 @default.
• W4220884345 creator A5015450747 @default.
• W4220884345 creator A5025351031 @default.
• W4220884345 creator A5026459010 @default.
• W4220884345 creator A5034972183 @default.
• W4220884345 creator A5035050460 @default.
• W4220884345 creator A5038422646 @default.
• W4220884345 creator A5039876591 @default.
• W4220884345 creator A5042439922 @default.
• W4220884345 creator A5043175553 @default.
• W4220884345 creator A5053983312 @default.
• W4220884345 creator A5054043060 @default.
• W4220884345 creator A5057566178 @default.
• W4220884345 creator A5076132601 @default.
• W4220884345 creator A5082786838 @default.
• W4220884345 creator A5085928527 @default.
• W4220884345 date "2022-02-15" @default.
• W4220884345 modified "2023-10-11" @default.
• W4220884345 title "Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC)" @default.
• W4220884345 doi "https://doi.org/10.1158/1538-7445.sabcs21-p5-16-11" @default.
• W4220884345 hasPublicationYear "2022" @default.
• W4220884345 type Work @default.
• W4220884345 citedByCount "0" @default.
• W4220884345 crossrefType "journal-article" @default.
• W4220884345 hasAuthorship W4220884345A5003095638 @default.
• W4220884345 hasAuthorship W4220884345A5011644667 @default.
• W4220884345 hasAuthorship W4220884345A5014596231 @default.
• W4220884345 hasAuthorship W4220884345A5015450747 @default.
• W4220884345 hasAuthorship W4220884345A5025351031 @default.
• W4220884345 hasAuthorship W4220884345A5026459010 @default.
• W4220884345 hasAuthorship W4220884345A5034972183 @default.
• W4220884345 hasAuthorship W4220884345A5035050460 @default.
• W4220884345 hasAuthorship W4220884345A5038422646 @default.
• W4220884345 hasAuthorship W4220884345A5039876591 @default.
• W4220884345 hasAuthorship W4220884345A5042439922 @default.
• W4220884345 hasAuthorship W4220884345A5043175553 @default.
• W4220884345 hasAuthorship W4220884345A5053983312 @default.
• W4220884345 hasAuthorship W4220884345A5054043060 @default.
• W4220884345 hasAuthorship W4220884345A5057566178 @default.
• W4220884345 hasAuthorship W4220884345A5076132601 @default.
• W4220884345 hasAuthorship W4220884345A5082786838 @default.
• W4220884345 hasAuthorship W4220884345A5085928527 @default.
• W4220884345 hasConcept C121608353 @default.
• W4220884345 hasConcept C126322002 @default.
• W4220884345 hasConcept C143998085 @default.
• W4220884345 hasConcept C2775930923 @default.
• W4220884345 hasConcept C2777176818 @default.
• W4220884345 hasConcept C2778504769 @default.
• W4220884345 hasConcept C2779744173 @default.
• W4220884345 hasConcept C2780482068 @default.
• W4220884345 hasConcept C530470458 @default.
• W4220884345 hasConcept C71924100 @default.
• W4220884345 hasConcept C98274493 @default.
• W4220884345 hasConceptScore W4220884345C121608353 @default.
• W4220884345 hasConceptScore W4220884345C126322002 @default.
• W4220884345 hasConceptScore W4220884345C143998085 @default.
• W4220884345 hasConceptScore W4220884345C2775930923 @default.
• W4220884345 hasConceptScore W4220884345C2777176818 @default.
• W4220884345 hasConceptScore W4220884345C2778504769 @default.
• W4220884345 hasConceptScore W4220884345C2779744173 @default.
• W4220884345 hasConceptScore W4220884345C2780482068 @default.
• W4220884345 hasConceptScore W4220884345C530470458 @default.
• W4220884345 hasConceptScore W4220884345C71924100 @default.
• W4220884345 hasConceptScore W4220884345C98274493 @default.
• W4220884345 hasIssue "4_Supplement" @default.
• W4220884345 hasLocation W42208843451 @default.
• W4220884345 hasOpenAccess W4220884345 @default.
• W4220884345 hasPrimaryLocation W42208843451 @default.
• W4220884345 hasRelatedWork W2605489431 @default.
• W4220884345 hasRelatedWork W2892043300 @default.
• W4220884345 hasRelatedWork W2897446380 @default.
• W4220884345 hasRelatedWork W2982700532 @default.
• W4220884345 hasRelatedWork W3161515104 @default.
• W4220884345 hasRelatedWork W3216407617 @default.
• W4220884345 hasRelatedWork W4206711305 @default.
• W4220884345 hasRelatedWork W4232409591 @default.
• W4220884345 hasRelatedWork W4297984276 @default.
• W4220884345 hasRelatedWork W4313452649 @default.
• W4220884345 hasVolume "82" @default.
• W4220884345 isParatext "false" @default.
• W4220884345 isRetracted "false" @default.
• W4220884345 workType "article" @default.